Biotechnology Divestitures in 2026

Axol Bioscience has acquired the ophthalmology business of Newcells Biotech, including its specialist team, facilities, and intellectual property for iPSC-derived retinal organoid and retinal pigment epithelium models. The deal expands Axol's ophthalmology capabilities and product portfolio to support biopharma, biotech and CRO customers across Europe and the United States, strengthening its position in ophthalmology drug discovery and safety testing.

Nexus Agriscience has acquired the hemp division and intellectual property portfolio of Biotech Institute, internalizing genetics, germplasm, and research talent to expand its molecular farming platform. The transaction brings issued and pending patents, proprietary germplasm, seed inventory, and key personnel into Nexus to accelerate development of hemp-derived natural ingredients for flavor, fragrance, and functional markets.